<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Antiarrhythmics</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8sMEGsKGkAAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAEBUlEQVRIx62V22tdRRTGf7Nn73P2ybntnNOe3NqkPTGgLTVUUZF6QatSLOKTPgqCIqLgQ0H/A1sQQbBYCBb1QfAxiC8tSO1FqHkwJVKtjdTGNraUmObsc9nXmfGh7cGYpM1D5nHWzPetteZb3wg2eB2YqYm4zSadsMtoboiNBH/3TE0awx6j+MRoxoTg/IYRvP19TQrJS0bzhdHGSyKFkLTtjSKwMjyiEz43ynhtP6bdjBCWyFobAf7eT7VhNF/q1FRbjYjmUohlCVPwnB+6FUxMTJipqSmUUhhjEGKd3bMT4ks/Y6oLBK2Yth8hHYtCJXOix7Nf7xLMzc0xOzvLzp078TyPNE3viW3QJPXzhNWbxFFKHCmMhoLn/FHodd48vGfhapdAacXQlkFK5dL6wIUm6fuTZPuvqDQhaMUYYyiVyuQr6rXDexYuAdi3tSv1ZJNs/R/CaszzT+1na88uXFnCEnJVgivBNN8uTJKmHQI/ptOOcXNZzMz9mOqFs90OHpipWcYwlo5P4ebnuOkrvr5wgrH+h3im7y36MzuwRXYZeKha/OhP0EkadFoxQSdGSotedR/+XwMc2XvKdNUFOFqZx6LKZWIiwjgkikNmLp/hm8sH+K1zjFTHXfBYdTi+eJArzXM0GxFxoBDCopLvo/fqEwi1XPkWkGqjFo2TgB1jOYZUKZTS/D1/ncmLh7jon0IbRWoiTi59ymzzJEEQE3cStNZsGxqlfPE57MBbOR8fP3hDGalOO9fq2DlBvmZw8xa2IxACGn6TydlD/O6f5OzSV/zif0cYhLQaEXGkKBbz7Ov/AOlXV1cxgBJRI3fuSTrpTawt18kWIZN1CFuaONI0w0WOXfsI43YIggh/KUSlhqxrMz74AkOZcWBm9QkH+Gw8NDLuITi+m0yzhluSyJzBLcpblUhFxywSRAEtPwQjsKVN30CNh0uvYuOubSHLtN3J0TO1j0pmBNuFbFWRK0gyPRZpktL2I5JQkclKakNlnh54g6ocvevUr/Ai2a7wineEkcJupA3S1Wg0nVZM2E6wbEF5U5G9Q++wI7sfR7h3N8HVNstykBfzH+KJEZwiWD0aIwxCgJ0R1Mu7GXOeJSuK93bZtQIle4D9pUNU5DC5jEsu55AvZakM5NicGyEj8uuz8bUCQgj67QfY671P3vEoeC69gy695U1U7NG7XV0pUwBjDJa1/JJlWWxzHuflzQe5FJ/GsgUVuZ2t8lEkTvfc0aNHb72flBhjVicQQqCUuvM3/M+WDVguWBrMVdDXEGZlBVEUrVCU9d9s5+fnaTQa2PZyPxEIhJaI1EEoZwX4ncynp6fXrmB4eJjR0VFarRbNZnP9P9rt9gohqNVq1Ov1ZbF/AZGev3hLJ2/zAAAAAElFTkSuQmCC)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\6.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Antiarrhythmics <a name='5:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<br>

<p>
<img src="./Pharmacology/pasted_image001.png">            ⇒ Dysfunction of impulse generation or conduction at any of a number of sites in the heart can cause an abnormality in cardiac rhythm.
</p>

<p>
→ <b>Abnormal automaticity</b> <br>
<ul>
<li>cells remain partially depolarized during diastole and can reach the firing threshold earlier than the normal SA cells</li>
</ul>
</p>

<p>
→ E<b>ffect of drugs on automaticity</b><br>
<ul>
<li>(by suppress automaticity by blocking either Na+ or Ca2+ channels to reduce the ratio of these ions to K+. → ↓ slope of PHASE 4 (depolarization) and/or ↑ the threshold of discharge to a less negative voltae = mostly on cells with ectopic pacemaker activity.</li>
</ul>
</p>

<p>
→ <b>Abnormalities in impulse conduction ( reentry )</b><br>
<ul>
<li>if a unidirectional block caused by myocardial injury or a prolonged refractory period results in an abnormal conduction pathway. </li>
<li>this  short-circuit pathway results in re-excitation of the ventricular muscle, causing premature contraction or sustained ventricular arrhythmia. </li>
</ul>
</p>

<p>
→ <b>Effects of drugs on conduction abnormalities </b><br>
<ul>
<li>prevent reentry by slowing conduction (Class I drugs) and/or increasing the refractory period (Class III drugs), thereby converting a unidirectional block into a bidirectional block.</li>
</ul>
</p>

<h1>III.  CLASS I ANTIARRHYTHMIC DRUGS</h1>

<p>
→ by blocking voltage-sensitive sodium (Na+) channels  = slows the rate of rise of Phase 0 of the action potential<br>
<ul>
<li>effect on the <b>resting</b>, fully polarized membrane because of their <b>higher affinity</b> for the <b>active and inactive channels</b> rather than for the resting channel</li>
</ul>
→generally cause a decrease in excitability and conduction velocity<br>
<ul>
<li>possible proarrhythmic effects = X in in patients with reduced left ventricular function and ischemic heart disease. </li>
</ul>
</p>

<h3>A.Use-Dependence:</h3>

<br>

<p>
→ bind more rapidly to open or inactivated sodium channels than to channels that are fully repolarized = blockade in tissues that are frequently depolarizing → without interfering with the normal, low-frequency beating of the heart → this property called <b>state-dependence</b>
</p>

<p>
<b>Class IA</b><br>
→  slow the rate of rise of the action potential → prolong the action potential →  increase the ventricular effective refractory period
</p>

<p>
<b>Class IB</b><br>
→ little effect on the rate of depolarization<br>
→ they ↓ APD by shortening the repolarization<br>
→ rapidly interact with Na channels
</p>

<p>
<b>Class IC</b><br>
→ depress the rate of rise of action potential<br>
→ slow the conduction <br>
→ they bind slowly to sodium channels
</p>

<h3>B.Arrythmias</h3>

<p>
→ inhibition of K channels = widens the action potential → prolonged QT interval on ECG → ↑ risk of developing drug-induced ventricular tachycardia<br>
→ caution when used with drugs that affect the QT interval such as (<i>quinidine and levofloxacin ) </i> or azole antifungals <i>(fluconazole and itroconazole)</i>
</p>

<h3>Quinidine: (IA)</h3>

<br>

<p>
→ prototype IA class but also show some Class III activity (percipitate arrythmias such us polymorphic ventricular tachycardi → ventricular fibrilation)<br>
→ calcium antagonist (<i>amiodraone and verapamil) </i>replace quinidin in clinical use
</p>

<p>
<b>1.MoA:</b><br>
→ bind to open and inactivated sodium channel and prevents sodium influx → slow the rapid upstroke phase 0<br>
→ inhibit potasium channels → slows conduction velocity and ↑ refractoriness<br>
<b>2.Therapeutic USe:</b><br>
→ artia,AV-junctionl,ventricular tachyarrhythmias<br>
<b>3.Pharmacokinetics:</b><br>
→ Quinidie sulfate rapidly and almost completely absorbed PO admin.<br>
→ extensive meteabolism by hepatic cythochrome P450 enzymes → active metabolites<br>
<b>4.AE:</b><br>
→ development of arrhythmia(torsades de pointes)<br>
→ SA/AV block or asystole<br>
→ nausea,vomiting,diarrhea,cinchonism<br>
→ mild -a-adregergic blocking (atropine-like effects)<br>
→ ↑ steady-state conc of digoxin by dispalcement (minor) &amp; ↓ digoxin reanl clearence (major effect)
</p>

<h3>Procainamide: (derivative of local anesthetic procaine) (IA)</h3>

<p>
<b>1.Actions:</b><br>
→ similar to quinidie
</p>

<p>
<b>2.Pharmacokinetics:</b><br>
→ well-absorbed PO admn.<br>
→ shrot half-lifef 2-3 hrs<br>
→ portion of drug acetylated → N-acetylprocainamide(NAPA) → ↑ APD and also produce CLASSIII side effects<br>
→ eliminated via the kidney  (dosages may need to adjust in patients with renal failure)
</p>

<p>
<b>3.AE:</b><br>
→ reversible lupus erythromataosus<br>
→ toxic conc → ventricular arrhythmias<br>
→ CNS side effects (depression,halluginaction,phycosis)
</p>

<h3>Disopyramide: (IA)</h3>

<p>
<b>1.Actions:</b><br>
→ similar to quinidine<br>
→ - intropic effect greater than previous drugs and unlike the latters produce peripheral vasonconstriction<br>
→ ↓ myocardial controctility in patients with impairmnt<br>
→ used in ventricular arrhythmias as alternative of the latter drugs<br>
→ also has some CLASSIII activity 
</p>

<p>
<b>2.Pharmacokinetics:</b><br>
→ half of the orally ingested drug excreted unchanged by the kidneys<br>
→ 30% of it converted by the liver → less active mono-N-dealkylated metabolite.
</p>

<p>
<b>3.AE:</b><br>
→ anticholinergic activity (dry mouth,urinary retentnion,blurred vision,constipation)
</p>

<h3>Lidocaine (IB)</h3>

<p>
→ rapidly associate and dissociate from sodium channels<br>
→ affect cardiac cells is depolarized or firing rapidly<br>
→ emergency treatment
</p>

<p>
<b>1.Actions:</b><br>
→ local anesthetic<br>
→ shorten Phase3 repolarizataion &amp; ↓APD
</p>

<p>
<b>2.Therapeutic Use:</b><br>
→ ventricular arrythmias which arising DURING myocardial ischemia<br>
→ does not markedly slow conduction thus has little effect on artial / AV junciton arrhythmias
</p>

<p>
<b>3.Pharmacokinetcs:</b><br>
→ IV because of extensive first-pass metabolism by the liver<br>
→ dealkylated and eliminated almost entirely by the liver
</p>

<p>
<b>4.AE:</b><br>
→ failry wide toxic to therapeutic ratio<br>
→ little impairment of left ventricular function &amp; no negative inotropic effect<br>
→ CNS
</p>

<h3>Mexiletin and Tocaidine: (IB)</h3>

<p>
→ effects similar to <i>lidocaine</i><br>
→ PO admin.<br>
→ Mexiletine used for chronic treatment of ventricular arrhythmias (which is associated with previosuly myocardial infranction)<br>
→ Tocainide used for treatment of ventricular tachyarrhythmias but has pulmonary toxicity → pulmonary 
</p>

<h3>Flecaidine: (IC)</h3>

<p>
→ slowly dissociate from resting sodium channels → prominent effects on normal heart rate<br>
→ treatment of refractory ventricular arrhythmias and prevention of parxysmal artial fibrilation/flutter by disabling symptoms of superventricular tachycardia
</p>

<p>
<b>1.Action:</b><br>
→ supress Phase 0in purkinje and myocardial fibers → slow conduction with minor effect on AP and refractoriness<br>
→ automaticity is reduced by an ↑ in the threshold potential rather than ↓ in the slope of Phase 4
</p>

<p>
<b>2.Therapeutic Use:</b><br>
→ refractory ventricular arrythmias (useful in supressing premature ventricular contraction)<br>
→ has - inotropic effect and can aggravate congestive heart failure
</p>

<p>
<b>3.Pharmacokinetics:</b><br>
→ absorbed orally , → minimal biotransformation <br>
→ half-life 16-20 hrs
</p>

<p>
<b>4.AE:</b><br>
→ dizziness,blurred vision,headache,nause
</p>

<br>

<p>
<img src="./Pharmacology/pasted_image006.png">
</p>

<h1>CLASS II ANTIARRHYTHMIC DRUGS:</h1>

<p>
→ b-adrenergic antagonsit <br>
→ diminish PHASE 4 depol → depressing automaticity → prolonging AV conduction → ↓ heart rate &amp; contractility<br>
→ treating tachycardias caused by ↑ sympathetic activity<br>
→ used for * artial flutter/fibrilation * AV-nodal tachycardia
</p>

<h3>Propanolol:</h3>

<p>
→ induce sudden arrhythmic death after myocardial infranction
</p>

<h3>Metoprolol:</h3>

<p>
→ β-adrenergic antagonist<br>
→ most widely used in cardiac arrythmias<br>
→ like propanolol → extensively metabolzied and has extensive CNS penetration
</p>

<h3>Esmolol:</h3>

<p>
→ very short acting β-blocker <br>
→ IV in acute arrhytmias occured during surgery or emergency situations.
</p>

<h1>CLASS III ANTIARRHYTHMIC DRUGS:</h1>

<br>

<p>
→ block potassium (K+) channels <br>
→ diminish the outward potassium current during repolarization of cardiac cells<br>
→ ↑ APD without alerting PHASE 0<br>
→ prolong the effective refractory period<br>
→ potential to induce arrhythmias
</p>

<h3>Amiodarone</h3>

<p>
<b>1.Action:</b><br>
→ contain iodine and structually related to thryoxine<br>
→ complex effects showing CLASS I,II,III and IV actions<br>
→ dominant prolongation of the APD and RF<br>
→ antianginal and antiarrhythmic activity
</p>

<p>
<b>2.Therapeutic Use</b><br>
→ severe refractory supraventricular and ventricular tachycardias<br>
→ managment of AF and Sinus rythm<br>
→ despite side effects is the most commonly employed antiarrhythmic
</p>

<p>
<b>3.Pharmacokinetics:</b><br>
→ incompletely absorbed PO admin.<br>
→ half-life of several weeks (50days)<br>
→ distributes extensively in adipose tissue<br>
→ long term therapy
</p>

<p>
<b>4.AE:</b><br>
→ variety of toxic effects after long -term use<br>
→ low doeses reduce toxicity<br>
→ interstitial pulmonary fibrosis, → GIT intolerance,tremor,ataxia,dizziness,hyper/hypo thyroism,liver toxicity,blue skin (by iodine accumulation on the skin )
</p>

<h3>Dronedarone:</h3>

<p>
→ ↓ lipophilic ,↓ tissue accumulation  and shorter half-life than Amiodarone<br>
→ Class I,II,III and IV actions<br>
→ GIT nature side effects including nause,vomiting and diarrhea<br>
→ less effective than Amiodarone in AF but has a better safety profile 
</p>

<h3>Sotalol:</h3>

<p>
→ potent non-selective β-blocker<br>
→ two stereoisomers (i-sotalol β blocker &amp; -d-sotalol CLASSIII antiarrhythmic activity )<br>
→ ↓ mortality of acute myocardial infranction
</p>

<p>
<b>1.Actions:</b><br>
→ blocks rapid outward potassium current (delayed rectifier) → ↑ APD and repolarizaiton → lengthening the effective refractory period
</p>

<p>
<b>2.Therapeutic Use:</b><br>
→ ↓ myocardial infranction<br>
→ supress ectopic beats to ↓ myocardial oxygen demands<br>
→ antifibrilatory effects (strong) in ischemic mycoardium<br>
→ more effective on preventing recurrence of arrhythmia &amp; ↓ mortality than <i>imipramine,mexiletine,procainamide,propafenone,qunidine </i>
</p>

<p>
<b>3.AE:</b><br>
→ lowest rate of acute or long-term ae<br>
→ potential(3/4p) of torsades de point syndrome
</p>

<h3>Dofetilide</h3>

<p>
→ first-line antiarrhythmic in patients with presisent AF and heart failure or those with coronary artery diseases with impaaired left ventricular function<br>
→ risk proarrhythmia <br>
→ along with amiodarone and b-blockers is the only antiarrhythmic agent tha tis recommended for AF<br>
→ half-life 10hrs → excrection urine → 80%unchanged &amp; 20% inactive or minimally active metabolites
</p>

<h1>CLASS IV ANTIARRHYTHMIC DRUGS:</h1>

<p>
→ Ca+2 channe-blockers <br>
→ ↓ inward current carreied by calcium → ↓ rate of PHASE 4<br>
→↓ conduction in tissues that are depended on calcium currents such as AV-node<br>
→ major effect : vascular smooth muscle and the heart
</p>

<h3>Verapamil and diltiazem</h3>

<br>

<p>
→ greater action on heart than on vasuclar smooth muscle whereas <i>Nifepidine </i>used to treat hypertension exerts a stronger effect on vasular smooth muscle than on the herat<br>
→ <i>Diltiazem </i>is intermediate in its acitons<br>
<b>1.Actions:</b><br>
→ Calcium → cells  via voltage-sensitive channels &amp; receptor-operated channels that are controlled by th binding of agonist (catecholamines to membrane receptors.<br>
→ Verapamil and Diltiazem are more effectings against voltage-sensitive channels → ↓ inward current that trigger cardiac contraction<br>
→ bind only to open ,depolirized channel thus preventing repolarization until the drug dissociate<br>
→ use-dependent  ( blocks when the heart beat hardly)<br>
→ slow condcution and prolong the effective refractory period
</p>

<p>
<b>2.Therapeutic Use</b><br>
→ artial arrhythmias<br>
→ supraventricular tachycardia<br>
→ ↓ ventricular rate on artial flutter/fibrilation<br>
→ hypertension and angina
</p>

<p>
<b>3.Pharmacokinetics</b><br>
→ absorbed PO admn<br>
→ extensively metabolized by the liver 
</p>

<p>
<b>4.AE:</b><br>
→ - inotropic properties CI to depressed cardiac function<br>
→ ↓ blood pressure (cuz of peripheral vasodilaton)
</p>

<p>
<img src="./Pharmacology/pasted_image002.png"><br>
<img src="./Pharmacology/pasted_image003.png">P<br>
<img src="./Pharmacology/pasted_image005.png"><br>
<img src="./Pharmacology/pasted_image004.png">
</p>

<br>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>61.6kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>130kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>114kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>281kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>228kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>120kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>97.2kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
